Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ashley Lane
Observed name:
Ashley R. Lane
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0000-0001-6402-8713
Observed ORCID:
0000-0001-6402-8713
OpenAlex ID:
A5047011859
Safe Handling: Implementing Hazardous Drug Precautions
2012
·
Ann Marie L. Walton
, Susan Mason
, et al.
·
Clinical journal of oncology nursing
·
33
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy
2024
·
Elizabeth S. Duke
, Diana Bradford
, et al.
·
Journal of Clinical Oncology
·
27
PDF
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer
2026
·
Yufan Liu
, Jeannette Nashed
, et al.
·
Clinical Cancer Research
·
14
PDF
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective
2023
·
Andrea C. Baines
, Maryam Sarraf Yazdy
, et al.
·
Clinical Cancer Research
·
14
PDF
Minimal Residual Disease (MRD) Data in Hematologic Malignancy Drug Applications and Prescribing Information: FDA Analysis
2021
·
Maryam Sarraf Yazdy
, Andrea C. Baines
, et al.
·
Blood
Show more works
View as search
Works count:
5
Citation count:
88
H-index:
4
I10-index:
4
Year
Topic
Type